Accent Therapeutics has revealed promising new preclinical data for its leading clinical programs, ATX-295 and ATX-559, at the prestigious 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The company, renowned for its specialized focus on RNA-modifying enzyme (RME) inhibitors, aims to transform cancer treatment by targeting these innovative molecular pathways. ATX-295 showed significant potential in inhibiting key cancer-related targets, while ATX-559 exhibited robust efficacy in preclinical models, highlighting Accent’s ongoing commitment to pioneering developments in oncology. By unveiling these compelling findings, Accent underscores its strategic goal to address unmet needs in cancer therapy, thereby enhancing clinical outcomes for patients. This presentation is a significant milestone for Accent Therapeutics as it continues to advance its pipeline of novel therapeutics designed to combat cancer more effectively.
PR NewswireNew data shows Tesla’s UK Sales Drop in February but Still Surpass BYD
March 5, 2026
In February, Tesla experienced a significant downturn in its UK sales, according to the latest data from New Automotive. Despite the plunge, Tesla managed to